These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19292815)

  • 41. Are micrometastases clinically relevant?
    Gusterson B
    Br J Hosp Med; 1992 Feb 19-Mar 3; 47(4):247-8. PubMed ID: 1591538
    [No Abstract]   [Full Text] [Related]  

  • 42. Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer.
    Nakamura R; Sakakibara M; Nagashima T; Sangai T; Arai M; Fujimori T; Takano S; Shida T; Nakatani Y; Miyazaki M
    Eur J Cancer; 2009 Aug; 45(12):2123-31. PubMed ID: 19398324
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Survival impact of integrative cancer care in advanced metastatic breast cancer.
    Block KI; Gyllenhaal C; Tripathy D; Freels S; Mead MN; Block PB; Steinmann WC; Newman RA; Shoham J
    Breast J; 2009; 15(4):357-66. PubMed ID: 19470134
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
    Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathological characteristics of triple-negative breast cancers.
    Sasaki Y; Tsuda H
    Breast Cancer; 2009; 16(4):254-9. PubMed ID: 19657711
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is immunohistochemistry less sensitive than quantitative reverse transcriptase polymerase chain reaction for hormone receptor status determination in breast cancer?
    Arnould L; Coudert B; Fumoleau P
    J Clin Oncol; 2009 Jun; 27(16):2733; author reply 2734-5. PubMed ID: 19380432
    [No Abstract]   [Full Text] [Related]  

  • 47. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation.
    Fehm T; Braun S; Muller V; Janni W; Gebauer G; Marth C; Schindlbeck C; Wallwiener D; Borgen E; Naume B; Pantel K; Solomayer E
    Cancer; 2006 Sep; 107(5):885-92. PubMed ID: 16874814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Commentary: hormone receptor testing in breast cancer: a distress signal from Canada.
    Allred DC
    Oncologist; 2008 Nov; 13(11):1134-6. PubMed ID: 18987048
    [No Abstract]   [Full Text] [Related]  

  • 49. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
    Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
    Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coordinates in the universe of node-negative breast cancer revisited.
    Schmidt M; Hengstler JG; von Törne C; Koelbl H; Gehrmann MC
    Cancer Res; 2009 Apr; 69(7):2695-8. PubMed ID: 19318558
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cancer is heterogeneous.
    Guinebretiere JM
    J Clin Oncol; 2009 Jun; 27(16):2732; author reply 2734-5. PubMed ID: 19380436
    [No Abstract]   [Full Text] [Related]  

  • 52. Bone marrow and lymph node evaluation.
    Tornquist SJ
    Vet Clin North Am Equine Pract; 2008 Aug; 24(2):261-83, v. PubMed ID: 18652955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.
    Broom RJ; Tang PA; Simmons C; Bordeleau L; Mulligan AM; O'Malley FP; Miller N; Andrulis IL; Brenner DM; Clemons MJ
    Anticancer Res; 2009 May; 29(5):1557-62. PubMed ID: 19443366
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
    Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
    Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic implications of positive nonsentinel lymph nodes removed during selective sentinel lymphadenectomy for breast cancer.
    Lang JE; Liu LC; Lu Y; Jenkins T; Hwang SE; Esserman LJ; Ewing CA; Alvarado M; Morita E; Treseler P; Leong SP
    Breast J; 2009; 15(3):242-6. PubMed ID: 19645778
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The value of bone marrow examination for tumor staging in breast cancer.
    Manegold C; Krempien B; Kaufmann M; Schwechheimer K; Schettler G
    J Cancer Res Clin Oncol; 1988; 114(4):425-8. PubMed ID: 3410881
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Presence of microscopic bone marrow cells may predict breast cancer recurrence.
    Oncology (Williston Park); 1991 Nov; 5(11):106. PubMed ID: 1837225
    [No Abstract]   [Full Text] [Related]  

  • 59. Diffusion-weighted imaging of breast cancer: correlation of the apparent diffusion coefficient value with prognostic factors.
    Kim SH; Cha ES; Kim HS; Kang BJ; Choi JJ; Jung JH; Park YG; Suh YJ
    J Magn Reson Imaging; 2009 Sep; 30(3):615-20. PubMed ID: 19711411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 3-Dimensional microarray analysis of estrogen signal-related genes in breast cancer tissues.
    Matsumoto M; Sakamoto H; Yamaguchi Y; Seino Y; Takei H; Kurosumi M; Sasano H; Yaegashi N; Hayashi S
    Anticancer Res; 2009 Oct; 29(10):3971-5. PubMed ID: 19846938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.